Biotechnology and Healthcare: A New Dawn? With Bob Bradway, CEO of Amgen

Biotechnology and Healthcare: A New Dawn? Wit...

Money Maze PodcastMoney Maze Podcast

Up next

AI and the Investment Edge: Enhancement, Replacement, or Reinvention?

It is already changing how firms conduct research, construct portfolios, manage risk, and make investment decisions. In this special compilation episode, we bring together three perspectives from across public markets, hedge funds and private markets, to explore how AI is transfo ...  Show more

 . 56min 17sec
A New Era: Richard Oldfield on the Future of Schroders and the Asset Management Industry

Most CEOs take years to make their mark. But after three decades dissecting and helping other people’s businesses at PwC, our guest today spent just two years inside Schroders before deciding it was time to sell the 222-year-old business. In this conversation, Richard Oldfield ex ...  Show more

 . 45min 9sec

Recommended Episodes

Human Health: Society and the Future of Biotech
The Next Five

Biotechnology is the use of biology in the production of new products, services, and organisms with the aim of improving human health and society. In 2024, the global biotech market was worth $1.68 trillion. By application, the health segment was responsible for just over half of ...  Show more

 . 30min 35sec
China’s Biotech Revolution
Thoughts on the Market

Our China Healthcare Analyst Jack Lin discusses how China’s biotech surge is reshaping healthcare, investment and innovation worldwide.Read more insights from Morgan Stanley.----- Transcript ----- Jack Lin: Welcome to Thoughts on the Market. I'm Jack Lin, from Morgan Stanley's Ch ...  Show more

 . 3min 13sec
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
The Readout Loud

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use ...  Show more

 . 31min 37sec
Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness
In Good Company with Nicolai Tangen

Can AI help us find cures for diseases we've never been able to treat? Nicolai Tangen speaks with Vasant 'Vas' Narasimhan, CEO of Novartis, about pioneering pharmaceutical innovation. They explore breakthrough cell and gene therapies, AI partnerships with leading tech companies, ...  Show more

 . 46min 34sec